Automate Your Wheel Strategy on GMED
With Tiblio's Option Bot, you can configure your own wheel strategy including GMED - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GMED
- Rev/Share 20.593
- Book/Share 32.7045
- PB 2.6406
- Debt/Equity 0.0271
- CurrentRatio 4.1299
- ROIC 0.0735
- MktCap 11625497003.0
- FreeCF/Share 4.3093
- PFCF 20.0576
- PE 27.4096
- Debt/Assets 0.0234
- DivYield 0
- ROE 0.0999
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | GMED | BofA Securities | Neutral | Buy | -- | $91 | Nov. 7, 2025 |
| Upgrade | GMED | Truist | Hold | Buy | -- | $93 | Nov. 7, 2025 |
| Resumed | GMED | Stifel | -- | Hold | -- | $64 | Oct. 28, 2025 |
| Downgrade | GMED | BTIG Research | Buy | Neutral | -- | -- | May 27, 2025 |
| Upgrade | GMED | BofA Securities | Underperform | Neutral | -- | $97 | Jan. 10, 2025 |
News
Globus Medical (GMED) is a Top-Ranked Growth Stock: Should You Buy?
Published: November 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Globus Medical: Straightening Its Back
Published: November 11, 2025 by: Seeking Alpha
Sentiment: Positive
Globus Medical has rebounded strongly, driven by accelerating earnings and successful integration of acquisitions like NuVasive and Nevro. The company delivered on robust Q3 results, with 7% organic growth and a significant hike in full-year adjusted earnings guidance to $3.80 per share. Despite a 35% share price surge, shares trades at a reasonable 21x earnings, supported by a strong balance sheet and ongoing synergy potential.
Read More
Globus Medical Stock Soars After Earnings. Where It's Seeing the Strength.
Published: November 07, 2025 by: Barrons
Sentiment: Positive
Shares of the medical technology company are headed for their largest same-day percentage increase on record.
Read More
Today's Market Moving Stocks: Affirm Holdings, Expedia, and Globus Medical
Published: November 07, 2025 by: 24/7 Wall Street
Sentiment: Neutral
The image featured for this article is © Thinkstock
Read More
Globus Medical (GMED) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Beyond analysts' top-and-bottom-line estimates for Globus Medical (GMED), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2025.
Read More
Globus Medical (GMED) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Globus Medical (GMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Is Wall Street Underestimating Globus Medical Stock's Potential?
Published: October 22, 2025 by: Forbes
Sentiment: Positive
Here's why we believe Globus Medical (GMED) stock merits attention as a value stock. It's currently trading approximately 33% below its 1-year high and is also trading at a PS multiple that falls below the average over the past 3 years.
Read More
GMED vs. SONVY: Which Stock Is the Better Value Option?
Published: October 14, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and SONOVA HOLDING (SONVY). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Here's Why Globus Medical (GMED) is a Strong Value Stock
Published: September 29, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Why Globus Medical (GMED) is a Top Value Stock for the Long-Term
Published: September 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Should You Hold Onto Globus Medical Stock in Your Portfolio for Now?
Published: September 04, 2025 by: Zacks Investment Research
Sentiment: Negative
GMED rides strong musculoskeletal demand and new launches, but faces currency headwinds and fierce competition.
Read More
Globus Medical Stock Up on Q2 Earnings & Revenue Beat, Margins Expand
Published: August 13, 2025 by: Zacks Investment Research
Sentiment: Positive
GMED posts strong Q2 with earnings and revenues, boosted by the Nevro acquisition and expanded margins.
Read More
Globus Medical, Inc. (GMED) Q2 2025 Earnings Call Transcript
Published: August 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Globus Medical, Inc. (NYSE:GMED ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Brian J. Kearns - Senior Vice President of Business Development & Investor Relations David C.
Read More
Stay Ahead of the Game With Globus Medical (GMED) Q2 Earnings: Wall Street's Insights on Key Metrics
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Globus Medical (GMED), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.
Read More
Globus Medical (GMED) Reports Next Week: Wall Street Expects Earnings Growth
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Globus Medical Announces Leadership Transitions and Preliminary Second Quarter 2025 Sales Results
Published: July 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
AUDUBON, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced that Keith Pfeil, Executive Vice President, Chief Operating Officer and Chief Financial Officer, has been appointed President and Chief Executive Officer effective July 18, 2025. Daniel Scavilla has resigned as President and Chief Executive Officer effective July 18, 2025, in order to pursue another opportunity. Additionally, Kyle Kline, Senior Vice President of Finance, has been appointed Senior Vice President and Chief Financial Officer.
Read More
GMED Unveils Next-Gen Oscillating System DuraPro: Stock to Gain?
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Globus Medical debuts DuraPro with Excelsius integration, boosting its Power Portfolio.
Read More
Globus Medical: Obtaining My Backing Again
Published: July 03, 2025 by: Seeking Alpha
Sentiment: Positive
Globus Medical shares have reset after a soft Q1 and Nevro acquisition, making valuations more attractive despite near-term dilution. The company's strong growth, driven by NuVasive integration and product launches, is offset by margin compression and recent earnings guidance cuts. A $500M buyback, net cash position, and sales multiples below 3x provide downside support and renewed appeal after a 25-30% share price pullback.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Globus Medical, Inc. - GMED
Published: June 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. (“Globus” or the “Company”) (NYSE: GMED). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Globus Medical, Inc. - GMED
Published: June 17, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , June 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. ("Globus" or the "Company") (NYSE: GMED). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Globus Medical, Inc. - GMED
Published: June 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. ("Globus" or the "Company") (NYSE:GMED). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims 0n Behalf of Investors of Globus Medical, Inc. - GMED
Published: June 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. (“Globus” or the “Company”) (NYSE: GMED). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Globus Medical, Inc. - GMED
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. (“Globus” or the “Company”) (NYSE: GMED). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Globus Medical, Inc. - GMED
Published: June 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. ("Globus" or the "Company") (NYSE:GMED). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Globus Medical, Inc. – GMED
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. (“Globus” or the “Company”) (NYSE: GMED). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Shareholders Alert: Investigation Into Globus Medical, Inc. (GMED) - Contact Levi & Korsinsky to Protect Your Rights
Published: May 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Globus Medical, Inc. ("Globus Medical, Inc.") (NYSE:GMED) concerning possible violations of federal securities laws. Globus issued a press release reporting its financial results for the first quarter of 2025 On May 8, 2025.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Globus Medical, Inc. - GMED
Published: May 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. ("Globus" or the "Company") (NYSE:GMED). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Did Globus Medical, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate- GMED
Published: May 23, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Globus Medical, Inc. ("Globus Medical, Inc.") (NYSE:GMED) concerning possible violations of federal securities laws. Globus issued a press release reporting its financial results for the first quarter of 2025 On May 8, 2025.
Read More
Investigation Alert: Globus Medical, Inc. (GMED) Under Scrutiny - Contact Levi & Korsinsky for Details
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Globus Medical, Inc. ("Globus Medical, Inc.") (NYSE:GMED) concerning possible violations of federal securities laws. Globus issued a press release reporting its financial results for the first quarter of 2025 On May 8, 2025.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Globus Medical, Inc. - GMED
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. ("Globus" or the "Company") (NYSE:GMED). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
About Globus Medical, Inc. (GMED)
- IPO Date 2012-08-03
- Website https://www.globusmedical.com
- Industry Medical - Devices
- CEO Daniel T. Scavilla
- Employees 5300